MedPage Today recently released a number of reports (July 2018) on a number of clinical studies regarding the effectiveness of anti-VEGF (vascular endothelial growth factor) treatment for people with age-related macular degeneration.
Although there are many anti-VEGF described in the literature like Bevacizumab, Ranibizumab, Pegaptanib, Anecortave acetate, VEGF-trap, Squalamine lactate, Combretastatin A4 Prodrug, AdPEDF, SiRNA, Cand5, TG100801, the ones that have been most studied are Bevacizumab (Avastin; Genentech, Inc., CA) Ranibizumab (Lucentis; Genentech, Inc., CA), and Pegaptanib sodium (Macugen; Eyetech, Inc., NY).
Here are a series of reports from MedPage Today that may be of interest to you:
Drug Slows Atrophy in Dry AMD: No vision improvement with complement C3 inhibitor
AMD Outcomes Lag in Real World: Minimal vision improvement with varied anti-VEGF practices
Laser, Anti-VEGF Therapy Similar for DME: Ranibizumab advantage at 2 years lost at 5
Device Extends Treatment Interval for AMD: Refill with anti-VEGF therapy pushed to 15 months